Evidence map›Paper›PMID 27552470›Full record

ReviewMenopause (New York, N.Y.)2016

Evaluation of the potential antidepressant effects of soybean isoflavones.

Mark Messina, Carey Gleason

Open access · greenAbstract readReview
In one paragraph

Review in Menopause (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Antidepressant Potential ofMolecules (Basel, Switzerland) · 2020
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mark Messina1Nutrition Matters, Inc, Pittsfield, MA 2University of Wisconsin School of Medicine and Public Health, Madison, WI.
Carey Gleason
University of Wisconsin–Madison · US

Funding

Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SAGER, MARK · 2009 to 2018
$16.2M
KEEPS Cognitive and Affective StudyR01AG029624 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ASTHANA, SANJAY · 2007 to 2013
$3.4M
NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG029624
6 · The paper itself

Abstract

objectiveThe aim of the study was to determine whether isoflavones affect depressive symptoms in women.

methodsLiterature searches were conducted to identify clinical and epidemiologic studies that evaluated the impact of soy intake and isoflavone exposure on depressive symptoms. References from identified studies were also evaluated to identify eligible studies.

resultsOnly limited epidemiologic research has evaluated the impact of soy or isoflavone intake on depression although several studies from China and Japan did find soy product intake was inversely related to risk of depression. Often times, soy was, however, evaluated only as a component of a summative dietary pattern (eg, a "Japanese" or "Healthy" diet). Of the 20 intervention studies identified, roughly half found statistically significant reductions in depressive symptoms in response to isoflavones although several had design weakness. Of those studies reporting a lack of antidepressant effects of isoflavones, design limitations likely contributed to the lack of efficacy. In all but two trials, assessment of depression was, however, a secondary outcome. It is notable that both trials in which depression was a primary outcome found isoflavones significantly improved symptoms.

conclusionsAlthough the data are inconsistent and limited, the clinical and epidemiologic evidence suggests that isoflavones may offer a safe, well-tolerated option for management of depression. Furthermore, the intervention doses used in the clinical studies fall well within the dietary range. The extant literature reveals key design features for future studies, which based upon the results of this review, are clearly warranted.

Indexed as

AdultAntidepressive AgentsDepressionFemaleGlycine maxHumansIsoflavonesMiddle AgedPhytotherapySoybean ProteinsAntidepressive AgentsIsoflavonesSoybean Proteins

Identifiers

PMID27552470
PMCPMC5181104
OpenAlexW2513995328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.